News
![](https://www.farmaindustriaticino.ch/files/2019/06/Giorgio-Calderari-160x160.jpg)
Creare alleanze produttive per i vaccini – L’opinione del Presidente FIT Giorgio Calderari
![](https://www.farmaindustriaticino.ch/files/2019/04/helsinn-160x160.jpeg)
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety
![](https://www.farmaindustriaticino.ch/files/2019/05/3-160x160.jpg)
Il rebus vaccini, tra ritardi e polemiche sui brevetti – Intervista a Giorgio Calderari, Presidente FIT
![](https://www.farmaindustriaticino.ch/files/2019/05/3-160x160.jpg)
Pharma Boardroom – Interview to Giorgio Calderari – Chairman, Farma Industria Ticino (FIT)
![](https://www.farmaindustriaticino.ch/files/2019/05/3-160x160.jpg)
Modem RSI Rete 1 – Covid: la corsa ai vaccini, intervista al Presidente FIT Giorgio Calderari
![](https://www.farmaindustriaticino.ch/files/2019/05/3-160x160.jpg)
Perché i vaccini sono in ritardo? Intervista a Giorgio Calderari, Presidente di FIT
![](https://www.farmaindustriaticino.ch/files/2019/05/3-160x160.jpg)
Tamponi a tappeto per i lavoratori? Intervista a Giorgio Calderari, Presidente di FIT e Group General Manager di Helsinn
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
![](https://www.farmaindustriaticino.ch/files/2017/02/logo_helsinn-160x160.png)
Linkedin